Currently, out of the existing stock ratings of Serge Belanger - 233 which are a Buy (96.28%), 9 which are a Hold (3.72%)

Serge Belanger

Work Performance Price Targets & Ratings Chart

Analyst Serge Belanger works at NEEDHAM and is covering the Healthcare sector with 403 price targets and ratings displayed on 31 stocks.

Serge Belanger's average stock forecast success ratio is 27.91% with an average time for price targets to be met of 149.33 days.

Most recent stock forecast was given on HRTX, Heron Therapeutics at 15-Nov-2023.

Wall Street Analyst Serge Belanger

Analyst best performing recommendations are on GRAY.
The best stock recommendation documented was for KALV at 1/26/2021. The price target of $25 was fulfilled within 14 days with a profit of $8.65 (52.91%) receiving and performance score of 37.79.

Average potential price target upside

of $28.23 (70.98%) on PTX.
of $16.18 (35.5%) on PCRX (PACIRA BIOSCIENCES).
of $15.69 (46.43%) on AERI (AERIE PHARMACEUTICALS).

AMPH Amphastar Pharmaceuticals CLSD Clearside Biomedical COLL Collegium Pharmaceutical CORI FLXN Flexion Therapeutics HRTX Heron Therapeutics KALV LQDA Liquidia Technologies OMER Omeros PCRX Pacira BioSciences RVNC Revance Therapeutics VRCA Verrica Pharmaceuticals ZGNX Zogenix AERI Aerie Pharmaceuticals AKBA Akebia Therapeutics BCRX BioCryst Pharmaceuticals CRXT CYTK Cytokinetics GRAY PHAS PhaseBio Pharmaceuticals TCDA Tricida TRVI XENE Xenon Pharmaceuticals ESPR Esperion Therapeutics PTX CRMD CorMedix AMAG ARQT Arcutis Biotherapeutics EOLS Evolus VRDN ZYNE Zynerba Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jacob Hughes (WELLS FARGO)